Predictive Markers of the Effects of Opioid Therapy (ABILITY)
Predictive Markers of the Effects of Opioid Therapy in Opioid naïve Patients With Chronic Pain: an International, Multi-centre, Observational Cohort Study (ABILITY)
The overall goal of the ABILITY study is to help improve pain diagnostics and treatment by developing an implementable clinical computerised decision support system based on individual patient characteristics.
The investigators hypothesize that successful pain control with opioids can be predicted before treatment initiation with advanced data analyses of data originating from pre-treatment EEG, QST and pain-related catastrophic thinking.
The primary objective of this study is the identification of markers that can be used to individualize treatment recommendations, i.e. to reliably predict the response of pain to opioids.
Markers are selected among the most promising data and machine-learning methods are used for the prediction. This includes determining the associations between a battery of selected pre-treatment clinical predictive markers and the analgesic effect of opioid treatment in opioid naïve chronic pain patients, including indication and responder identification.
The key secondary objectives are as follows: to investigate pre-treatment clinical predictive markers as predictors of opioid treatment efficacy and effectiveness in terms of the following:
- Pain intensity and unpleasantness
- Use of rescue analgesics
- Physical functioning
- Global improvement and satisfaction with treatment
調査の概要
状態
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Ljubljana、スロベニア、1000
- Ljubljana University Medical Centre, Department of Anaesthetics and Surgical Intensive Care
-
-
-
-
-
Aarhus C、デンマーク、8000
- Department of Rheumatology, Aarhus University Hospital
-
Give、デンマーク、7323
- Friklinikken
-
Ringsted、デンマーク、4100
- Hospitalet Valdemar
-
-
-
-
Pellenberg
-
Leuven、Pellenberg、ベルギー、3212
- KU Leuven and the Leuven Centre for Algology & Pain Management
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Pain duration ≥ 3 months.
- Minimum baseline pain intensity ≥ 4 on a 0-10 numerical rating scale (over the past week).
- Maximum baseline pain intensity < 9 on a 0-10 numerical rating scale (over the past week).
- Prescribed opioid treatment (ATC: N02)
- Anticipated to stay on prescribed opioid treatment throughout the study, i.e. >14 days.
- Anticipated to stay on any concomitant non-opioid treatment throughout the study, i.e. >14 days.
- Subject may be male or female, age >18 years old.
- Is willing and able to comply with study procedures as judged by the site investigator.
- Subject has voluntarily signed and dated the study-specific informed consent form, approved by an Independent Ethics Committee, after the nature of the study has been explained and the subject has had the opportunity to ask questions. The informed consent form must be signed before any study-specific procedures are performed.
Exclusion Criteria:
- Has a mental incapacity or language barriers precluding adequate understanding of study procedures.
- Is considered by the site investigator unsuitable to participate in the study for any other reason, for instance due to a significant serious underlying condition.
- Recently received opioids on a daily basis (within the last 10 weeks).
- Current alcohol or substance abuse, according to the site investigator's medical judgement.
- Is anticipated to undergo a painful procedure(s) (e.g. surgery) during the study, which can interfere with the experience of the chronic pain condition for which the subject is to receive opioids.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:コホート
- 時間の展望:見込みのある
コホートと介入
グループ/コホート |
---|
Opioid analgesics
Opioid treatment is determined, prescribed, modified and discontinued at the sole discretion of the treating physician at each research site; regardless of generic name, manufacturer, constituent components, route of administration, and dosing schedule (including titration and run-in periods).
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Reduction of chronic pain assessed by 0-10 numerical rating scale (NRS) scores
時間枠:After 14-days of opioid treatment
|
The absolute and percentage change from baseline in ratings of average pain in the past week at Day 14.
Of note, a percentage change of ≥30% is considered clinically significant.
|
After 14-days of opioid treatment
|
Improvement of health-related quality of life assessed by QLQ-C30 scores
時間枠:After 14 days of opioid treatment
|
The absolute and percentage change from baseline in ratings of health-related quality of life in the past week at Day 14.
A subjectively significant change in QLQ-C30 scores is one that is ≥10 from baseline.
|
After 14 days of opioid treatment
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
BPI worst pain in the past week
時間枠:Day 14 post-treatment
|
Change from baseline
|
Day 14 post-treatment
|
BPI least pain in the past week
時間枠:Day 14 post-treatment
|
Change from baseline
|
Day 14 post-treatment
|
BPI current pain in the past week
時間枠:Day 14 post-treatment
|
Change from baseline
|
Day 14 post-treatment
|
BPI pain severity in the past week
時間枠:Day 14 post-treatment
|
Change from baseline
|
Day 14 post-treatment
|
BPI pain interference score
時間枠:Day 14 post-treatment
|
Change from baseline
|
Day 14 post-treatment
|
Improvement score
時間枠:Day 14 post-treatment
|
Proportion with score >4
|
Day 14 post-treatment
|
Concomitant and rescue medication
時間枠:Until 14 days post-treatment
|
Until 14 days post-treatment
|
|
Adverse events
時間枠:Until 14 days post-treatment
|
Number (%) of the following:
|
Until 14 days post-treatment
|
協力者と研究者
スポンサー
捜査官
- スタディチェア:Asbjørn M Drewes, MD, PhD, DMSci、Aalborg University Hospital, Denmark
- スタディディレクター:Anne E Olesen, MSc (Pharm), PhD、Aalborg University Hospital, Denmark
- スタディディレクター:Kasper Grosen, MHSc, PhD、Aarhus University / Aarhus University Hospital, Denmark
- 主任研究者:Mogens Pfeiffer-Jensen, MD, PhD、Aarhus University Hospital, Denmark
- 主任研究者:Michael Kamp-Jensen, MD, PhD、Hospitalet Valdemar, Denmark
- 主任研究者:Bart Morlion, MD, PhD、University of Leuven / University Hospitals Leuven, Belgium
- 主任研究者:Gorazd Pozlep, MD、Ljubljana University Medical Centre, Slovenia
- 主任研究者:Torsten Jonsson, MD、Hospitalet Valdemar, Denmark
出版物と役立つリンク
便利なリンク
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
慢性の痛みの臨床試験
-
Dexa Medica Group完了